Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-03-15 DOI:10.1016/j.clgc.2025.102336

Teja Ganta , Jonathan F. Anker , Eric Miller , Himanshu Joshi , Che-Kai Tsao , William K. Oh

{"title":"Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors","authors":"Teja Ganta , Jonathan F. Anker , Eric Miller , Himanshu Joshi , Che-Kai Tsao , William K. Oh","doi":"10.1016/j.clgc.2025.102336","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Immune checkpoint inhibitors (ICIs) have been shown to have limited efficacy in unselected populations of patients with metastatic castration-resistant prostate cancer (mCRPC). In the phase III clinical trial CONTACT-02, a novel regimen combining cabozantinib and ICI improved progression-free survival in patients with mCRPC; however, due to its lack of survival benefit, it has not yet gained regulatory approval. In this retrospective series of patients with mCRPC without high tumor mutational burden or microsatellite instability treated with cabozantinib and ICI, the data indicate that a subpopulation exists with an exceptional long-term response, including some patients maintained on therapy for more than 30 months. The study further characterizes this subpopulation and can guide treatment selections for patients with limited options as oncologists and regulatory bodies continue to evaluate the risks and benefits of widespread adoption of this regimen.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102336"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000370","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

•
Immune checkpoint inhibitors (ICIs) have been shown to have limited efficacy in unselected populations of patients with metastatic castration-resistant prostate cancer (mCRPC). In the phase III clinical trial CONTACT-02, a novel regimen combining cabozantinib and ICI improved progression-free survival in patients with mCRPC; however, due to its lack of survival benefit, it has not yet gained regulatory approval. In this retrospective series of patients with mCRPC without high tumor mutational burden or microsatellite instability treated with cabozantinib and ICI, the data indicate that a subpopulation exists with an exceptional long-term response, including some patients maintained on therapy for more than 30 months. The study further characterizes this subpopulation and can guide treatment selections for patients with limited options as oncologists and regulatory bodies continue to evaluate the risks and benefits of widespread adoption of this regimen.

查看原文本刊更多论文

卡博赞替尼和免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌患者的异常反应特征

•免疫检查点抑制剂（ICIs）已被证明在转移性去势抵抗性前列腺癌（mCRPC）患者的未选择人群中疗效有限。在III期临床试验CONTACT-02中，cabozantinib和ICI联合的新方案改善了mCRPC患者的无进展生存期；然而，由于缺乏生存效益，尚未获得监管部门的批准。在这一系列的回顾性研究中，没有高肿瘤突变负担或微卫星不稳定性的mCRPC患者接受卡博桑替尼和ICI治疗，数据表明，存在一个亚群，具有特殊的长期反应，包括一些持续治疗超过30个月的患者。随着肿瘤学家和监管机构继续评估广泛采用该方案的风险和益处，该研究进一步确定了这一亚人群的特征，并可以指导有限选择的患者的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.